Factors associated with age at tau pathology onset and time from tau onset to dementia
Heston, M. B.; Teague, J. P.; Cody, K. A.; Deming, Y.; Ruiz de Chavez, E.; Morse, J.; Chin, N. A.; Engelman, C. D.; Chappell, R. J.; Langhough, R. E.; Gleason, C. E.; Clark, L. R.; Zuelsdorff, M. L.; Betthauser, T. J.; Alzheimer's Disease Neuroimaging Initiative,
Show abstract
INTRODUCTIONElevated tau is temporally proximal to dementia onset but less is known about factors influencing T+ onset age and time to dementia following T+ in Alzheimers disease. We used sampled iterative localized approximation (SILA) estimated T+ onset age (ETOA) to investigate factors associated with T+ age and time from T+ to dementia onset in ADNI. METHODSUsing SILA-estimated A+ and T+ onset ages derived from 18F-Flortaucipir, 18F-Florbetapir, and 18F-Florbetaben PET and Cox proportional hazards and accelerated failure time models, we analyzed APOE, sex, amyloid burden, age, educational attainment, and literacy associations with ETOA and time from T+ to dementia. RESULTSHigher amyloid, APOE-{varepsilon}4, lower education, and lower literacy associated with younger ETOA. Older ETOA and higher amyloid associated with shorter time from T+ to dementia. DISCUSSIONThis work highlights the prognostic value of ETOA and the need to better characterize factors contributing to ETOA and dementia onset in AD.
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators 95%
- Association between lifestyle at different life periods and brain integrity in older adults 93%
- Susceptibility to postmortem (co)-pathologies in antemortem atrophy-based subtypes of Alzheimer’s disease 93%
Similar papers in this journal
- Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts 97%
- Tau-first subtype of Alzheimer's disease consistently identified across in vivo and post mortem studies 97%
- A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests 96%